1
|
Tyler CJ, Guzman M, Lundborg LR, Yeasmin S, Zgajnar N, Jedlicka P, Bamias G, Rivera-Nieves J. Antibody secreting cells are critically dependent on integrin α4β7/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis. Mucosal Immunol 2022; 15:109-119. [PMID: 34433904 PMCID: PMC8732264 DOI: 10.1038/s41385-021-00445-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2021] [Revised: 08/02/2021] [Accepted: 08/07/2021] [Indexed: 02/04/2023]
Abstract
T and B cells employ integrin α4β7 to migrate to intestine under homeostatic conditions. Whether those cells differentially rely on α4β7 for homing during inflammatory conditions has not been fully examined. This may have implications for our understanding of the mode of action of anti-integrin therapies in inflammatory bowel disease (IBD). Here, we examined the role of α4β7 integrin during chronic colitis using IL-10-/- mice, β7-deficient IL-10-/-, IgA-deficient IL-10-/- mice, and antibody blockade of MAdCAM-1. We found that α4β7 was predominantly expressed by B cells. β7 deficiency and MAdCAM-1 blockade specifically depleted antibody secreting cells (ASC) (not T cells) from the colonic LP, leading to a fecal pan-immunoglobulin deficit, severe colitis, and alterations of microbiota composition. Colitis was not due to defective regulation, as dendritic cells (DC), regulatory T cells, retinaldehyde dehydrogenase (RALDH) expression, activity, and regulatory T/B-cell cytokines were all comparable between the strains/treatment. Finally, an IgA deficit closely recapitulated the clinical phenotype and altered microbiota composition of β7-deficient IL-10-/- mice. Thus, a luminal IgA deficit contributes to accelerated colitis in the β7-deficient state. Given the critical/nonredundant dependence of IgA ASC on α4β7:MAdCAM-1 for intestinal homing, B cells may represent unappreciated targets of anti-integrin therapies.
Collapse
Affiliation(s)
- Christopher J. Tyler
- San Diego VA Medical Center, San Diego, CA USA ,grid.266100.30000 0001 2107 4242Division of Gastroenterology, University of California San Diego, La Jolla, CA USA
| | - Mauricio Guzman
- San Diego VA Medical Center, San Diego, CA USA ,grid.266100.30000 0001 2107 4242Division of Gastroenterology, University of California San Diego, La Jolla, CA USA
| | - Luke R. Lundborg
- San Diego VA Medical Center, San Diego, CA USA ,grid.266100.30000 0001 2107 4242Division of Gastroenterology, University of California San Diego, La Jolla, CA USA
| | - Shaila Yeasmin
- San Diego VA Medical Center, San Diego, CA USA ,grid.266100.30000 0001 2107 4242Division of Gastroenterology, University of California San Diego, La Jolla, CA USA
| | - Nadia Zgajnar
- San Diego VA Medical Center, San Diego, CA USA ,grid.266100.30000 0001 2107 4242Division of Gastroenterology, University of California San Diego, La Jolla, CA USA
| | - Paul Jedlicka
- grid.241116.10000000107903411Department of Pathology, University of Colorado Denver, Denver, CO USA
| | - Giorgos Bamias
- grid.5216.00000 0001 2155 0800GI Unit, 3rd Academic Department of Internal Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Jesús Rivera-Nieves
- San Diego VA Medical Center, San Diego, CA USA ,grid.266100.30000 0001 2107 4242Division of Gastroenterology, University of California San Diego, La Jolla, CA USA
| |
Collapse
|
2
|
Lundborg LR, Guzman M, Tyler CJ, Yeasmin S, Rivera-Nieves J. Sphingosine-1-phosphate lyase inhibition exacerbates DSS-induced colitis via promoting the disruption of epithelial barrier. The Journal of Immunology 2020. [DOI: 10.4049/jimmunol.204.supp.79.24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
S1P is a bioactive sphingolipid that participates as a critical regulator of many physiological processes, mainly in lymphocyte egress from lymphoid tissue, mediated by S1P gradients through the activity of S1P lyase (SPL). Inhibition of both S1P-specific receptors and Lyase activity has been shown to improve inflammatory conditions during Crohn’s-like ileitis. In contrast to this, initial observations show acute DSS-induced colitis was aggravated by SPL inhibition. Here we investigate whether the inhibition of Lyase in the intestinal epithelium is the cause of the exacerbation of colitis.
To induce global or epithelial cell specific SPL deletion, Gt(rosa)-cre or Villin-cre Sgpl1 transgenic mice were administered with tamoxifen (80 mg/kg) by oral gavage for 5 consecutive days. Then, mice were treated with DSS (2.5%) in drinking water for 7 days. Clinical features and histological scores were recorded. Permeability assays were performed to evaluate integrity of the intestinal epithelium with fluorescein isothiocyanate (FITC)-dextran 4 kDa.
Significant differences in the histopathological features (inflammation and injury) in colon were observed between Gt(rosa)Cre+/−/SPL−/− or VillinCre+/−/SPL−/− mice compared to their respective controls (without tamoxifen treatment) (n>10, p<0.001). In addition, these animals presented higher levels of epithelial permeability since the concentration of serum (FITC)-dextran was higher than their respective controls (n>10, p<0.001).
In conclusion, in the acute model of DSS-induced colitis the presence of S1P in the intestinal epithelium exacerbates inflammatory conditions, demonstrating that there could be differences in the mechanisms with chronic models of IBD.
Collapse
Affiliation(s)
| | | | | | | | - Jesus Rivera-Nieves
- 2Univ. of California San Diego. School of Medicine, Department of medicine, Division of Gastroenterology and Hepathology
| |
Collapse
|
3
|
Tyler CJ, Guzman M, Lundborg LR, Yeasmin S, Perez-Jeldres T, Yarur A, Behm B, Dulai PS, Patel D, Bamias G, Rivera-Nieves J. Inherent Immune Cell Variation Within Colonic Segments Presents Challenges for Clinical Trial Design. J Crohns Colitis 2020; 14:1364-1377. [PMID: 32239151 PMCID: PMC7533898 DOI: 10.1093/ecco-jcc/jjaa067] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND AND AIMS Intestinal biopsy sampling during IBD trials represents a valuable adjunct strategy for understanding drug responses at the tissue level. Given the length and distinctive embryonic origins of the proximal and distal colon, we investigated whether inherent regional differences of immune cell composition could introduce confounders when sampling different disease stages, or pre/post drug administration. Here, we capitalise on novel mass cytometry technology to perform deep immunophenotyping of distinct healthy colonic segments, using the limited numbers of biopsies that can be harvested from patients. METHODS Biopsies [2.8 mm] were collected from the caecum, transverse colon, descending colon, and rectum of normal volunteers. Intestinal leukocytes were isolated, stained with a panel of 37 antibodies, and mass cytometry data acquired. RESULTS Site-specific patterns of leukocyte localisation were observed. The proximal colon featured increased CD8+ T cells [particularly resident memory], monocytes, and CD19+ B cells. Conversely, the distal colon and rectum tissues exhibited enrichment for CD4+ T cells and antibody-secreting cells. The transverse colon displayed increased abundance of both γδ T cells and NK cells. Subsets of leukocyte lineages also displayed gradients of expression along the colon length. CONCLUSIONS Our results show an inherent regional immune cell variation within colonic segments, indicating that regional mucosal signatures must be considered when assessing disease stages or the prospective effects of trial drugs on leukocyte subsets. Precise protocols for intestinal sampling must be implemented to allow for the proper interpretation of potential differences observed within leukocyte lineages present in the colonic lamina propria.
Collapse
Affiliation(s)
- Christopher J Tyler
- Inflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA,San Diego VA Medical Center, San Diego, CA, USA
| | - Mauricio Guzman
- Inflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA,San Diego VA Medical Center, San Diego, CA, USA
| | - Luke R Lundborg
- Inflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA,San Diego VA Medical Center, San Diego, CA, USA
| | - Shaila Yeasmin
- Inflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA,San Diego VA Medical Center, San Diego, CA, USA
| | - Tamara Perez-Jeldres
- Universidad Católica de Chile, Santiago, Chile,Hospital San Borja Arriarán, Santiago, Chile
| | - Andres Yarur
- Division of Gastroenterology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Brian Behm
- Division of Gastroenterology, University of Virginia, Charlottesville, VI, USA
| | | | - Derek Patel
- San Diego VA Medical Center, San Diego, CA, USA
| | - Giorgos Bamias
- GI Unit, 3rd Academic Department of Internal Medicine, National and Kapodistrian University of Athens, Sotiria Hospital, Athens, Greece
| | - Jesús Rivera-Nieves
- Inflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA,San Diego VA Medical Center, San Diego, CA, USA,Corresponding author: Jesús Rivera-Nieves, MD, Inflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, 9500 Gilman Drive Bldg. BRF-II Rm. 4A32, San Diego, CA 92093-0063. Tel.: 858.534.5495; fax: 858.246.1788;
| |
Collapse
|
4
|
Karuppuchamy T, Tyler CJ, Lundborg LR, Pérez-Jeldres T, Kimball AK, Clambey ET, Jedlicka P, Rivera-Nieves J. Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn's-Like Ileitis by Suppressing Thymocyte Maturation. Inflamm Bowel Dis 2020; 26:216-228. [PMID: 31807751 PMCID: PMC6943703 DOI: 10.1093/ibd/izz174] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Indexed: 02/07/2023]
Abstract
BACKGROUND Lymphocytes recirculate from tissues to blood following the sphingosine-1-phosphate (S1P) gradient (low in tissues, high in blood), maintained by synthetic and degradative enzymes, among which the S1P lyase (SPL) irreversibly degrades S1P. The role of SPL in the intestine, both during homeostasis and IBD, is poorly understood. We hypothesized that modulation of tissue S1P levels might be advantageous over S1P receptor (S1PR) agonists (eg, fingolimod, ozanimod, etrasimod), as without S1PR engagement there might be less likelihood of potential off-target effects. METHODS First we examined SPL mRNA transcripts and SPL localization in tissues by quantitative reverse transcription polymerase chain reaction and immunohistochemistry. The in vivo effects of the SPL inhibitors 4-deoxypyridoxine hydrochloride (30 mg/L) and 2-acetyl-4 (tetrahydroxybutyl)imidazole (50 mg/L) were assessed through their oral administration to adult TNF∆ARE mice, which spontaneously develop Crohn's-like chronic ileitis. The effect of SPL inhibition on circulating and tissue lymphocytes, transcriptional regulation of proinflammatory cytokines, and on the histological severity of ileitis was additionally examined. Tissue S1P levels were determined by liquid chromatography-mass spectrometry. Mechanistically, the potential effects of high S1P tissue levels on intestinal leukocyte apoptosis were assessed via terminal deoxynucleotidyl transferase dUTP nick end-labeling assay and annexin 5 staining. Finally, we examined the ability of T cells to home to the intestine, along with the effects of SPL inhibition on cellular subsets within immune compartments via flow and mass cytometry. RESULTS S1P lyase was ubiquitously expressed. In the gut, immunohistochemistry predominantly localized it to small intestinal epithelia, although the lamina propria leukocyte fraction had higher mRNA transcripts. Inhibition of SPL markedly increased local intestinal S1P levels, induced peripheral lymphopenia, downregulated proinflammatory cytokines, and attenuated chronic ileitis in mice. SPL inhibition reduced T and myeloid cells in secondary lymphoid tissues and the intestine and decreased naïve T-cell recruitment. The anti-inflammatory activity of SPL inhibition was not mediated by leukocyte apoptosis, nor by interference with the homing of lymphocytes to the intestine, and was independent of its peripheral lymphopenic effect. However, SPL inhibition promoted thymic atrophy and depleted late immature T cells (CD4+CD8+ double positive), with accumulation of mature CD4+CD8- and CD4-CD8+ single-positive cells. CONCLUSIONS Inhibition of the S1P lyase alters the S1P gradient and attenuates chronic ileitis via central immunosuppression. SPL inhibition could represent a potential way to tame an overactive immune response during IBD and other T-cell-mediated chronic inflammatory diseases.
Collapse
Affiliation(s)
- Thangaraj Karuppuchamy
- Inflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, California, USA
| | - Christopher J Tyler
- Inflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, California, USA
| | - Luke R Lundborg
- Inflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, California, USA
| | - Tamara Pérez-Jeldres
- Universidad Católica de Chile, Santiago, Chile
- Hospital San Borja Arriarán, Santiago, Chile
| | - Abigail K Kimball
- Department of Anesthesiology Aurora, Colorado, USA
- Department of Pathology, Aurora, Colorado, USA
| | - Eric T Clambey
- Department of Anesthesiology Aurora, Colorado, USA
- Department of Pathology, Aurora, Colorado, USA
| | - Paul Jedlicka
- Department of Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA
| | - Jesús Rivera-Nieves
- Inflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, California, USA
- Gastroenterology Section, San Diego VA Medical Center, La Jolla Village Drive, San Diego, California, USA
| |
Collapse
|